Evidence map›Paper›PMID 40447952›Full record

ReviewApplied microbiology and biotechnology2025

Engineering of Corynebacterium glutamicum for the synthesis of aromatic compounds.

Jan Marienhagen

Abstract readReview
In one paragraph

Review in Applied microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Single Mutation inMicroorganisms · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Jan MarienhagenInstitute of Bio- and Geosciences, Forschungszentrum Jülich, IBG-1: Biotechnology, 52425, Jülich, Germany. j.marienhagen@fz-juelich.de.ORCID http://orcid.org/0000-0001-5513-3730

Funding

Bundesministerium für Bildung und Forschung 031B1134AH2020 European Research Council 638718
6 · The paper itself

Abstract

A significant proportion of industrially important small molecules are aromatic, and the majority of these compounds are produced chemically, relying heavily on fossil resources. In bacteria and plants, the shikimate pathway and related biosynthetic routes serve as the primary sources of aromatic compounds. Microbial cell factories, which are poised to play a central role in the emerging bio-based economy, provide a sustainable alternative for producing commercially valuable aromatics from renewable resources. Corynebacterium glutamicum, already established as an industrial workhorse for the large-scale production of various amino acids, can be engineered to overproduce aromatic compounds derived from the shikimate pathway. Furthermore, the functional integration of heterologous or synthetic pathways enables access to high-value natural products, such as plant polyphenols and other polyketides. This review highlights recent advancements in the metabolic engineering of C. glutamicum for the sustainable production of these aromatic compounds. KEY POINTS: • C. glutamicum's high tolerance to aromatic compounds is key to aromatics production. • Detailed physiological insights enable access to shikimate pathway-derived products. • Diverse plant (poly)phenols and other aromatic polyketides can be produced.

Indexed as

Corynebacterium glutamicumHydrocarbons, AromaticMetabolic EngineeringBiosynthetic PathwaysPolyketidesShikimic AcidHydrocarbons, AromaticPolyketidesShikimic AcidAromaticAromatic compoundCorynebacterium glutamicumMetabolic engineeringPlant polyphenolPolyketideShikimate pathway

Identifiers

PMID40447952
PMCPMC12125101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.